Drug Profile
Uproleselan - GlycoMimetics
Alternative Names: APL-106; GMI-1271; Uproleselan injection - Apollomics/GlycoMimetics; Uproleselan sodium - GlycoMimeticsLatest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator GlycoMimetics
- Developer Apollomics; GlycoMimetics; National Cancer Institute (USA); University of California, Davis
- Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
- Mechanism of Action E-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II Gastrointestinal disorders
- Phase I/II Acute biphenotypic leukaemia; COVID-19 pneumonia; Deep vein thrombosis; Myelodysplastic syndromes
- No development reported Chronic myeloid leukaemia; Multiple myeloma; Solid tumours; Stem cell mobilisation
Most Recent Events
- 03 Jan 2024 Apollomics completes enrolment in its phase-III clinical trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in China (IV) (NCT05054543)
- 09 Dec 2023 Efficacy and adverse events data from a phase Ib/II trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Adverse events data from a phase II trial in Gastrointestinal disorders at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)